Genmab — Februar 2018
-
Seattle Genetics (SGEN) Q4 2017 Results - Earnings Call Transcript - with prominent mention and some further colour on tisotumab vedotin - https://seekingalpha.com/article/4143833-seattle-genetics-sgen-q4-2017-results-earnings-call-transcript?part=single
-
Vi har set vedvarende positivt nettokøb fra A/B - gruppen på det seneste. Det hjælper i hvert fald altid på mit humør.
-
Det endda samtidigt med en stigende short.
-
@ Helge, vi ved jo også, at bare fordi de opkøber så kan det jo være de akkumulerer til et større dump! Så jeg vil først være rolig når ligningen hedder nettoopkøb + levereing af aktier tilbage. (reference til FPC)
-
Henrikfrost...Vi har endnu til gode at se større aggressivitet fra shortinteresserne i aktien.
-
De er meget humane.
-
Helge, enig!...Hvis man har været i FPC så er Genmabs shortere en flok spejderpiger til sammenligning. Vi krydser fingre for gode nyheder.
-
-
The Earnings Call Transcript which E L linked at 08:45 is very interesting. SGEN seems very euphoric about TV. They even talk about first line possibilities. It looks like SGEN see much greater value in TV than Genmab!
-
GeorgeBest, Can you put some word on what this could possibly mean for Genmab?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind